Physician profile
Randolph P Sumner
NPI 1700871555
$13,369.10
in general payments reported to CMS, 2019-2025
53 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $2,412 · 2021: $2,647 · 2022: $2,348 · 2023: $2,083 · 2024: $1,617 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,914.75 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,497.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $999.43 | 2021-2024 | |
| Glaxosmithkline, LLC. | $975.50 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $945.92 | 2019-2024 | |
| Amgen INC. | $721.55 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $554.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $499.57 | 2019-2024 | Verquvo, Belsomra, Gardasil |
| Lilly USA, LLC | $483.24 | 2019-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $419.59 | 2019-2021 | |
| Amarin Pharma, INC. | $386.03 | 2019-2022 | |
| Allergan, INC. | $327.83 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $289.50 | 2019-2023 | Seglentis, Livalo |
| Phathom Pharmaceuticals, INC. | $272.18 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $269.69 | 2023-2025 | Auvelity |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.